The time is now: accounting for time-of-day effects to improve reproducibility and translation of metabolism research
- PMID: 40097742
- DOI: 10.1038/s42255-025-01237-6
The time is now: accounting for time-of-day effects to improve reproducibility and translation of metabolism research
Abstract
The constant expansion of the field of metabolic research has led to more nuanced and sophisticated understanding of the complex mechanisms that underlie metabolic functions and diseases. Collaborations with scientists of various fields such as neuroscience, immunology and drug discovery have further enhanced the ability to probe the role of metabolism in physiological processes. However, many behaviours, endocrine and biochemical processes, and the expression of genes, proteins and metabolites have daily ~24-h biological rhythms and thus peak only at specific times of the day. This daily variation can lead to incorrect interpretations, lack of reproducibility across laboratories and challenges in translating preclinical studies to humans. In this Review, we discuss the biological, environmental and experimental factors affecting circadian rhythms in rodents, which can in turn alter their metabolic pathways and the outcomes of experiments. We recommend that these variables be duly considered and suggest best practices for designing, analysing and reporting metabolic experiments in a circadian context.
© 2025. Springer Nature Limited.
Conflict of interest statement
Competing interests: S.A.B. is a cofounder and scientific advisor of Ona Therapeutics. G.S.H. is a scientific advisory board member of Crescenta Biosciences. J.S.T. is a founder and scientific advisory board member of Synchronicity Pharma. J.D.R. is a paid adviser and/or stockholder in Colorado Research Partners, L.E.A.F. Pharmaceuticals, Faeth Therapeutics and Empress Therapeutics; a paid consultant of Pfizer; a founder and stockholder in Marea Therapeutics; and a founder, director and stockholder of Farber Partners, Raze Therapeutics and Sofro Pharmaceuticals. S.K. serves as a scientific advisory board member of Moonwalk Biosciences. V.D.L. has equity interest in L-Nutra, a company making medical food, and has filed patents related to fasting-mimicking diets and their medical use. M.A.L. is on the advisory board of Pfizer and serves on the advisory board and is a cofounder of Flare Therapeutics. E.V. is a scientific cofounder of Napa Therapeutics and BHB Therapeutics and serves on the scientific advisory board of Seneque. J.A. is a board member of NOV Metapharma, a founder and/or consultant for Vandria and Amprenta Therapeutics and consults for OrsoBio, MetroBiotech and Amazentis (now Timeline); none of these companies develop products regulating circadian activity. D.J.D. has served as a consultant or speaker within the past 12 months for Amgen, AstraZeneca, Boehringer Ingelheim, Kallyope, Novo Nordisk and Pfizer. S.P. is the author of the books the Circadian Code and the Circadian Diabetes Code and is a scientific advisor to Hooke London, Avadel and WndrHlth. Other authors have no conflict of interests to declare.
References
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
